Hidehito Horinouchi Shared ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC
Hidehito Horinouchi and Martin Reck

Hidehito Horinouchi Shared ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC

Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:

“ASCO 2025 Abstract
Lung Cancer Poster
Unraveling relatlimab-specific biology: Biomarker analyses in pts with metastatic NSCLC treated with 1L nivolumab + RELA high-dose and chemotherapy 
Martin Reck, Poster Bd7, Abstr8527″

Abstract Title: Unraveling relatlimab (RELA)-specific biology: Biomarker analyses in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with 1L nivolumab (NIVO) + RELA high-dose (HD) and platinum-doublet chemotherapy (PDCT).

Authors: Martin Reck, Jaclyn Neely, Vamsidhar Velcheti, Sheida Hayati, Annie Yu, Korey Demers, Michael Schenker, Manuel Cobo, Mauricio Burotto, Francisco Orlandi, Priyanka Kasbekar, Anila Qureshi, Charlie Garnett-Benson, Nicolas Girard

Read Full Abstract on ASCO.

ASCO

More Posts Featuring Hidehito Horinouchi on OncoDaily.